Herpesvirus Intestinal Treatment Prevents Neurodegeneration via Exosomes

← USPTO Patent Applications

Treating herpesvirus-mediated intestinal dysfunction for prevention of age-related neurodegeneration

Application US20260098267A1 Kind: A1 Apr 09, 2026

Inventors

Richelle Gayle Cutler

Abstract

Human herpesviruses can infect barrier and immune cells of the intestinal tract to cause microbiome dysbiosis and inflammation. Microbiome dysbiosis can affect the availability of nutrients required for normal brain function. Inflammation can compromise the intestinal barrier and lead to microbial translocation. Microbial translocation can cause brain infection or a mimicry auto-immune response. The embodiments restrict herpesvirus activity and injury by 1) the oral administration of exosomes containing factors to inhibit viral activity and restore homeostasis, and 2) the oral administration of recombinant bacteria that produce exosomes containing factors to inhibit viral activity and restore homeostasis. Another embodiment is the treatment of alpha-HHVs mediated intestinal dysfunction by nucleoside analogs, such as famciclovir, which may be combined with anti-viral exosome therapy.

CPC Classifications

C12N 15/1133 C12N 1/20 A61K 9/0053 A61K 45/06 C12N 2310/122 C12N 2310/141

Filing Date

2025-09-30

Application No.

19346483

View original document →